Tamoxifen and other estrogen receptor modulators are used both as adjuvant therapy for estrogen receptor / progesterone receptor (ER/PR) positive breast cancer and as a risk reduction strategy in women at increased risk of breast cancer. This evidence concerns the gene PGR and breast carcinoma.